| Name | 2-Hydroxypropanoic acid-4-amino-5-fluoro-3-[5-(4-methyl-1-piper azinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (2:1) |
|---|---|
| Synonyms |
Dovitinib (TKI-258) Dilactic Acid
Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (2:1) Dovitinib Dilactic acid 2-Hydroxypropanoic acid - 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (2:1) TKI258 Dilactic acid Dovitinib Dilacticacid |
| Description | Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C27H33FN6O7 |
|---|---|
| Molecular Weight | 572.59 |
| Exact Mass | 572.239502 |
| PSA | 209.36000 |
| LogP | 2.44450 |
| Storage condition | -20℃ |